Brief: Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502
21/07/2026 07:20
BRIEF-Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502 July 21 (Reuters) - Innate Pharma SA IPH.PA:
INNATE PHARMA ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE 1 DOSE ESCALATION STUDY OF IPH4502, A NOVEL NECTIN-4 EXATECAN ANTIBODY-DRUG CONJUGATE (ADC)
INNATE PHARMA - PRELIMINARY DATA FROM 76 PATIENTS EXPECTED BY YEAR-END
INNATE PHARMA - IPH4502 SHOWS FAVORABLE SAFETY PROFILE WITH HEMATOLOGICAL TOXICITY TO DATE
Source text: ID:nBw53HHrba
Further company coverage: IPH.PA
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Innate Pharma SA
See all newsBrief: Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502
France's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member